CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
OptoCeutics is developing a non-invasive light therapy to promote the clearance of beta-amyloid, a key factor in Alzheimer's Disease. Their method uses alternating wavelengths of light to stimulate brain activity without causing discomfort.
While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone.
However, there are still significant roadblocks ahead as current drugs do not untap sizeable improvements in AD patients.
This is primarily due to the challenge of minimizing the impact of irreversible brain damage in later dementia st…
OPTOCEUTICS APS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
